Food and Drug Administration
Oncologic Drugs Advisory Committee
September 17, 1999
Slides
Disclaimer
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Doxorubicin HCL Liposome, Proposed Indication: "First line Treatment of Metastatic Breast Cancer in Combination With Cyclophosphamide," Bristol-Myers Co. htm ppt
Taxol (paclitaxel) for Adjuvant Treatment of Node Positive Breast Cancer, Dr. David Tuck, MD, Bristol-Myers Squibb Co. htm ppt
Adjunvant Chemotherapy of Breast Cancer, Dr. Larry Norton, MD, Memorial Sloan-Kettering Cancer Ctr. htm ppt
Effect of Taxol (paclitaxel) and Doxorubicin Dose on Disease Free and overall Survival of Patients With Node Positive Breast Cancer, Dr. I Craig Henderson, U. of California htm ppt
Taxol (paclitaxel) for Adjuvant Treatment of Node Positive Breast Cancer, Concluding Remaks, Dr. Renzo Canetta, MD, Bristol-Myers Squibb Co. htm ppt
Taxol for Adjuvant Breast Cancer Therapy, FDA Review Team htm ppt